Lately, recent studies have demonstrated that antitumor immunity influences the efficacy of HER2-targeted therapy, highlighting the potential role of anti-PD1 therapy as a therapeutic target in HER2 + BC subtypes [5]. This evidence concerns the gene ERBB2 and breast cancer.